Imatinib Devatis (Imatinib)

Imatinib is a targeted antineoplastic agent that acts on specific tyrosine‑kinase driven malignancies.

• Chronic myeloid leukemia: suppresses BCR‑ABL driven proliferation, leading to hematologic and cytogenetic remission.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia: blocks leukemic cell growth and improves remission rates.
• Gastrointestinal stromal tumor: inhibits c‑KIT and PDGFR signaling, reducing tumor size and disease progression.

• Imatinib binds competitively to the ATP‑binding site of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This blockade halts proliferative signaling pathways, induces apoptosis of malignant cells, and impedes tumor angiogenesis, resulting in disease control in cancers driven by these kinases.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Edema: peripheral swelling, especially in the ankles.
• Muscle cramps: intermittent tightness or pain.
• Fatigue: persistent tiredness.
• Diarrhea: loose stools.
• Rash: mild skin eruption.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or jaundice.
• Cardiotoxicity: reduced left‑ventricular ejection fraction.
• Severe neutropenia: markedly low white‑blood‑cell count.
• Hemorrhage: bleeding tendencies.
• Pulmonary arterial hypertension: increased pressure in lung arteries.
• Anaphylaxis: rare severe allergic reaction.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly.

• Baseline labs: obtain CBC, liver and renal function tests.
• Cardiac monitoring: evaluate ejection fraction in patients with cardiac risk.
• Drug interactions: review concomitant medications for CYP3A4 inhibitors/inducers.
• Pregnancy: avoid use unless benefits outweigh potential fetal risk.
• Breastfeeding: contraindicated; advise against nursing while on therapy.
• Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Imatinib interacts with several drug classes that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels and risk toxicity.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower efficacy by reducing drug exposure.

Moderate Interactions (Monitor Closely)

• Acid‑reducing agents (e.g., proton pump inhibitors, antacids): can affect absorption; separate dosing by at least 2 hours.
• Anticoagulants (e.g., warfarin): may increase bleeding risk; monitor INR.
• Vaccines (live attenuated): potential reduced immune response; consider timing.